CYDY - CytoDyn completes enrollment in COVID-19 long-hauler trial

CytoDyn ([[CYDY]] -11.6%) has announced the full enrollment of a Phase 2 trial evaluating Vyrologix (Leronlimab) in the treatment of patients with prolonged COVID-19 symptoms.The randomized, double-blind, placebo-controlled study involving 56 patients is designed to evaluate the safety and efficacy of Leronlimab after eight (8) weekly doses of the experimental therapy.The final treatment for the last enrolled patient is expected in early June and results are anticipated in July, the company said.Leronlimab is a monoclonal humanized IgG4 antibody that blocks cellular receptor CCR5, which is believed to be important in HIV infection, tumor metastases, and other diseases.This week, CytoDyn announced the approval from the Philippine FDA allowing the use of Leronlimab in additional 28 critically ill COVID-19 patients under compassionate use.

For further details see:

CytoDyn completes enrollment in COVID-19 long-hauler trial